ASP Isotopes PET Lab Revenue Grows Over 50% in First Half of Year, Isotope Enrichment Facilities Advance Toward Commercial Production

ASP Isotopes Inc. recently released a letter to shareholders outlining operational progress across its business segments ahead of the company's second-quarter 2026 financial results announcement.

The company stated that its PET lab segment achieved organic revenue growth of more than 50% in the first half of 2026 compared to the same period in 2025. Based on current expectations, the segment's full-year 2026 revenue is projected to be approximately $14 million, up from $6 million in 2025. PET-related operations are typically closely associated with radiopharmaceutical preparation, molecular imaging, and nuclear medicine diagnostic applications.

On the isotope front, ASP Isotopes stated that its silicon-28 and ytterbium-176 enrichment facilities have entered the final stage before commercial production, with first product deliveries expected in the second half of 2026. The company's Chief Executive Officer Paul Mann noted that the related delays primarily stemmed from equipment performance issues at original suppliers, rather than from the company's core enrichment technology itself.

The company also expects to commence helium production at its subsidiary Renergen by September 30, 2026. Drilling operations for Phase 1 of Renergen's Virginia Gas Project have achieved the required cumulative flow rates sufficient to support the process plant operating at rated capacity. Upon completion of Phase 1, based on current expected pricing, the company projects annual revenue of approximately $27 million from helium and liquefied natural gas sales.

Regarding offtake arrangements, Renergen has entered into an agreement with an Asian industrial gas company to purchase helium equivalent to approximately 15% of Phase 1 planned helium capacity, at an initial base price exceeding $600 per thousand cubic feet.

ASP Isotopes also announced plans to host a Capital Markets Day in London on September 8, 2026, coinciding with the World Nuclear Association Symposium. The company's subsidiary Quantum Leap Energy is also continuing to advance its plans to list as a standalone entity. Following the recent transaction completion, ASP Isotopes holds approximately $140.7 million in QLE convertible notes and retains 100% of QLE common equity.